Washington, D.C.—The U.S. Food and Drug Administration (FDA) released data today on a dedicated website from six studies reflecting a two-month period in response to a requirement under the “FDA Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data” to make transparent the percentage of female and minority participation in clinical trials for medications intended for all populations. “I am pleased by this action step by FDA,” said Phyllis Greenberger, President and CEO of the Society for Women’s Health Research (SWHR®), “but the news is discouraging. The data validates the concern we have expressed to the FDA for 25 years.”
Washington, D.C. – The Society for Women’s Health Research (SWHR®) is pleased to announce that Dr. Judith Wolf, Chief Medical Officer of Vermillion, Inc., in Austin, Texas, has joined the SWHR Board of Directors. Her 3-year term begins immediately.
A New Survey from the Society for Women’s Health Research Reveals Cost and Lack of Insurance Are Biggest Barriers to Mammograms; A Majority of Women Are Unaware the ACA Requires Mammography Screenings at No Cost Sharing Washington, DC – October 29, 2014 – Four in... read more